{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:46:00Z","timestamp":1768812360874,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.seizure.2020.04.016","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T21:45:31Z","timestamp":1589147131000},"page":"75-79","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East"],"prefix":"10.1016","volume":"79","author":[{"given":"Ghassan","family":"Hmaimess","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Dirani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"Hotait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan A.","family":"Beydoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassim","family":"Nasreddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.seizure.2020.04.016_bib0005","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40263-018-0523-7","article-title":"Lacosamide: a review in focal-onset seizures in patients with epilepsy","volume":"32","author":"Hoy","year":"2018","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.seizure.2020.04.016_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1586\/14737175.9.1.33","article-title":"Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures","volume":"9","author":"Beydoun","year":"2009","journal-title":"Expert Rev. Neurother."},{"issue":"12","key":"10.1016\/j.seizure.2020.04.016_bib0015","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000008126","article-title":"Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures","volume":"93","author":"Farkas","year":"2019","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2020.04.016_bib0020","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pediatrneurol.2010.12.003","article-title":"Experience with lacosamide in a series of children with drug-resistant focal epilepsy","volume":"44","author":"Guilhoto","year":"2011","journal-title":"Pediatr. Neurol."},{"issue":"1","key":"10.1016\/j.seizure.2020.04.016_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejpn.2011.08.007","article-title":"Preliminary efficacy and safety of lacosamide in children with refractory epilepsy","volume":"16","author":"Heyman","year":"2012","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.seizure.2020.04.016_bib0030","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.yebeh.2017.11.024","article-title":"The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting","volume":"79","author":"Sanmart\u00ed-Vilaplana","year":"2018","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.seizure.2020.04.016_bib0035","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.yebeh.2018.04.020","article-title":"Efficacy and tolerability of treatment with lacosamide: postmarketing experience from the Middle East region","volume":"84","author":"Arabi","year":"2018","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.seizure.2020.04.016_bib0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.yebeh.2011.02.005","article-title":"Efficacy and tolerability of oral lacosamide as adjunctive therapy in pediatric patients with pharmacoresistant focal epilepsy","volume":"20","author":"Gavatha","year":"2011","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.seizure.2020.04.016_bib0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1177\/0883073812436741","article-title":"Lacosamide in refractory mixed pediatric epilepsy: a prospective add-on study","volume":"27","author":"Rastogi","year":"2012","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.seizure.2020.04.016_bib0050","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpn.2013.08.006","article-title":"Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy","volume":"18","author":"Grosso","year":"2014","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"6","key":"10.1016\/j.seizure.2020.04.016_bib0055","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.braindev.2013.07.003","article-title":"Lacosamide as an adjunctive therapy in pediatric patients with refractory focal epilepsy","volume":"36","author":"Kim","year":"2014","journal-title":"Brain. Dev."},{"issue":"4","key":"10.1016\/j.seizure.2020.04.016_bib0060","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2165\/11636260-000000000-00000","article-title":"Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy","volume":"12","author":"Casas-Fern\u00e1ndez","year":"2012","journal-title":"Drugs R&D"},{"issue":"4","key":"10.1016\/j.seizure.2020.04.016_bib0065","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.pediatrneurol.2014.07.004","article-title":"Efficacy and tolerability of lacosamide as an adjunctive therapy in children with refractory partial epilepsy","volume":"51","author":"Pasha","year":"2014","journal-title":"Pediatr. Neurol."},{"issue":"3","key":"10.1016\/j.seizure.2020.04.016_bib0070","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.seizure.2012.12.009","article-title":"Lacosamide in pediatric and adult patients: comparison of efficacy and safety","volume":"22","author":"Verrotti","year":"2013","journal-title":"Seizure"},{"issue":"12","key":"10.1016\/j.seizure.2020.04.016_bib0075","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/11587550-000000000-00000","article-title":"A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs","volume":"24","author":"Sake","year":"2010","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.seizure.2020.04.016_bib0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide","volume":"29","author":"Villanueva","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"9","key":"10.1016\/j.seizure.2020.04.016_bib0085","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131120301230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:54:45Z","timestamp":1761011685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131120301230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":17,"alternative-id":["S1059131120301230"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2020.04.016","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of treatment with lacosamide in children: Postmarketing experience from the Middle East","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2020.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}